-
EU Biotech Act, AI in healthcare & faster clinical trials: legal update from Sorainen
This year promises to be an interesting one for a range of stakeholders. Several regulatory developments are underway across the EU and the Baltics, particularly in the areas of biotechnology and medical devices. In this month’s Life Sciences & Healthcare newsletter, we bring you: key aspects of the long-awaited European Commission proposals for the Biotech […]
-
The EU pushes AI and R&D transformation — key updates for Life Sciences leaders
The EU is taking steps to integrate AI into healthcare and research by directing efforts to establish centres of excellence. Additionally, a stronger focus is being put on strengthening the European Research Area and developing innovation-driven policies. In this newsletter, our Life Sciences & Healthcare team will spotlight key legislative changes in our region and […]
-
Disputes, directives & the UPC: legal trends impacting Life Sciences & Healthcare sector
The number of litigations and disputes is increasing in the life sciences sector worldwide, including across Europe and our region. This trend is driven by regulatory reforms, patent complexities, and the establishment of the Unified Patent Court (UPC). This newsletter highlights the key litigation trends that the businesses should be aware of and that have […]
-
From compulsory licensing to AI in healthcare: what’s changing in the Baltics and beyond?
In this newsletter, we discuss legal news which broadly impacts the life sciences and healthcare sector, as well as updates specifically relevant to research and development. This time we are covering: At the EU level, the Council is now ready to begin negotiations with the European Parliament about the “pharma package”, and a regulation is […]
-
Life Sciences & Healthcare newsletter, April 2025
In this newsletter, we discuss legal news which affects the pharmaceutical and pharmacy sector. The Commission’s proposal on the Critical Medicines Act will hopefully provide tools for member states to avoid supply chain issues in relation to critical medicines. Interpretations by the Court of Justice of the European Union assist market players to navigate in […]